These proteomic panels provided strong prognostic value, surpassing A/T/N biomarkers and even tau-PET based measures (Fig. 5–6; Fig. S7), currently considered the most accurate predictors of longitudinal AD trajectories11,48. This evidence concerns the gene MAPT and Alzheimer disease.